Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217, pTau181, pTau231, and total tau (tTau) protein measured directly from blood samples—delivering unprecedented sensitivity and specificity for the study of neurodegenerative diseases.
Phosphorylated tau has emerged as a critical biomarker for early detection and monitoring of Alzheimer's disease and other tauopathies. The new additions to the CNS Disease 120 Panel are specifically designed to detect brain-derived forms of pTau, overcoming the limitations of current assays that cannot distinguish between peripheral and central tau species. This allows for the simultaneous measurement of two suites of multiple pTaus and tTau species, one specific for brain-derived and one combining brain- and peripheral tissue-derived Tau species.
"Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology," said Dr. Yuling Luo, CEO, Founder and Chairman of Alamar Biosciences. "By integrating assays for pTau217, pTau181, pTau231, and total tau into our NULISAseq CNS Disease 120 Panel, we are enabling scientists to explore the full spectrum of tau pathology with exceptional sensitivity and throughput. This advancement is poised to accelerate biomarker-driven research and drug development in Alzheimer's Disease and related neurodegenerative disorders."
"The ability to detect brain-derived pTau species directly from blood represents a transformative step in the early detection and monitoring of Alzheimer's Disease (AD) and related disorders," said Nicholas Ashton, Ph.D., Director of Neurodegenerative Biomarker Research at Banner Health. "Until now, we've been unable to differentiate between brain-derived and peripheral pTaus in a multiplexed manner. Recent evidence has underlined the importance of being able to detect brain-derived pTau for greater specificity for AD. Alamar's new CNS panel offers an unprecedented opportunity to further improve the diagnostic accuracy and clinical utilities of these biomarkers, which will dramatically impact patient care and clinical research."
Alamar Biosciences remains committed to partnering with the neuroscience community to unlock biomarker insights that drive earlier diagnosis, patient stratification, and therapeutic monitoring.
For more information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' portfolio of proteomic solutions, visit www.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ -- On 31 st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that outlines shared priorities, strategies, and recommendations to elevate the standard of lung cancer care across diverse health systems. Held on the eve of World Lung Cancer Day, the initiative involved over 43 contributors, including clinicians, academics, patient advocates, and health organisations across 14 APAC health systems. Launch Highlights and Key Voices The APAC Lung Cancer Policy Consensus was launched with keynote contributions from: Lung cancer remains the leading cause of cancer-related deaths in the APAC region, and accounts for nearly 60% of global cases. With regional incidence projected to exceed 1.8 million by 2040, the need for a cohesive, regional strategy to combat the disease has never been more urgent. Furthermore, survival rates in the APAC region often lag behind global benchmarks, with five-year survival rates frequently below 20%. This fragmented landscape highlights the critical need for a coordinated approach, one that addresses the unique epidemiological, environmental, and healthcare challenges within the region. The APAC Lung Cancer Policy Consensus is the result of an extensive collaborative process involving two expert working sessions, one patient workshop and a final expert voting session, with input from patients, clinicians and academic leaders across the region. The consensus lays out a unified policy framework anchored in five core principles, all aimed at driving sustainable, equitable improvements in lung cancer prevention, detection, treatment, and stigma reduction across the region. Importantly, the APAC Consensus aligns closely with the Global Lung Cancer Consensus, which was first ratified at the 9th International Lung Cancer Network in 2023. By endorsing this global statement, the APAC region reaffirms its commitment to improving lung cancer outcomes. The Five Global Principles Anchoring the : A Region-Specific Approach to Lung Cancer Care The APAC Lung Cancer Policy Consensus is not just a regional adaptation of global recommendations; it is a comprehensive response to the distinct challenges faced by the APAC region. Unlike Western health systems that primarily focus on smoking-related lung cancer, the APAC region must contend with a higher prevalence of lung cancer in never-smokers due to factors such as environmental pollutants, and genetic predispositions. Moreover, the region's healthcare systems are highly heterogeneous, ranging from well-resourced settings with cutting-edge cancer care to lower-resource environments building on basic cancer services. Given these disparities, a one-size-fits-all approach would be ineffective. The APAC Lung Cancer Policy Consensus presents a regionally tailored action plan that offers specific strategies and targets to improve lung cancer care and outcomes, ensuring that every health system in the region, regardless of its capacity, can make progress toward the shared goals. "We call on policymakers, healthcare leaders, and stakeholders across the APAC region to urgently prioritise and implement policies that improve lung cancer outcomes. While the specific solutions will vary across health systems, this consensus provides a shared foundation to guide national efforts. By acting now and adapting these recommendations to local contexts, we can foster a future where healthcare systems of all sizes work together to overcome regional challenges." said Judy Li, Consortium Manager at ASPIRE for Lung Cancer. Looking Ahead The launch of the APAC Lung Cancer Policy Consensus marks the start of a sustained regional effort to transform lung cancer care in the Asia-Pacific region. Over the coming months, ASPIRE for Lung Cancer and its partners will continue to engage with policymakers, healthcare leaders, and patient advocacy groups to ensure that the consensus principles are translated into concrete action, with measurable outcomes. Through this regional collaboration, APAC aims to drive meaningful change that will improve survival rates and quality of life for lung cancer patients across the region. For more details about the APAC Lung Cancer Policy Consensus or to learn how you can get involved in advancing lung cancer care in your region, visit About ASPIRE for Lung Cancer ASPIRE (Asia Pacific Policy Review and Engagement) for Lung Cancer is a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms. We advocate for prioritising lung cancer in government action plans, aiming to drive transformative changes that enhance patient access and care. We believe in the influence of collaboration and collective action to drive positive change. We therefore work with governments, agencies, NGOs and patient groups, bringing together multi-disciplinary experts to improve health outcomes for lung cancer patients in the APAC region.
Korea Herald
a day ago
- Korea Herald
Medit to Reveal New Medit i900 Mobility, Powered by True Mobility
SEOUL, South Korea, Aug. 1, 2025 /PRNewswire/ -- Medit ( a global leader in digital dentistry, today introduces the Medit i900 Mobility, a next-generation intraoral scanner designed to deliver simplicity and true mobility to clinical workflows. The Medit i900 Mobility is the latest addition to Medit's scanner lineup, thoughtfully designed to move with the pace of everyday dentistry, wherever care happens. At the heart of the experience are four core pillars of mobility: improved clinical efficiency and workflow fluidity optimized for chair-to-chair and room-to-room use, instant usability with lite installation, enhanced patient interaction during the scanning process and a minimal learning curve that makes adoption easy from the first scan. The i900 Mobility transforms how clinicians work, move and connect with patients by combining precision with ease of use. At the core of this experience is Medit Link Express, the company's first iPad-native companion app, designed to simplify scan-and-send workflows through an intuitive, user-friendly interface. With real-time scan viewing and built-in patient engagement, the app transforms the iPad into a seamless bridge between clinician and patient — immediate, effortless and mobile. Purpose-built for flexibility, the i900 Mobility pairs best-in-class software with compact, responsive hardware, ready to support chairside scanning, team collaboration and care beyond the traditional clinic setting. Designed for a new standard of mobility, key highlights of the i900 Mobility include: Together, the i900 Mobility and Medit Link Express redefine what mobility means in dentistry, reshaping how scanning fits into everyday practice. Whether at the chairside, between clinical staff, easily moving between environments, or stepping beyond the traditional clinic, it's a more fluid, responsive way to work. This is scanning, powered by true mobility. Pre-orders for the Medit i900 Mobility open August 1, 2025, with shipping set to begin from September 1, availability may vary by region. Medit Link Express will be available for download from the Apple App Store starting September 1. For more information and updates, visit About Medit Medit is a global provider of 3D intraoral scanners and digital dentistry solutions based on proprietary technology. The company supports collaborative workflows between dental clinics and labs through innovative hardware and software solutions. Headquartered in Seoul, South Korea, since 2000, Medit has a strong global presence through its offices in the Americas and Europe and a distributor network spanning over 100 countries.
Korea Herald
2 days ago
- Korea Herald
Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025
SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 31st that it participated in the Alzheimer's Association International Conference (AAIC 2025), showcasing its flagship brain imaging analysis AI solutions. At the conference, Jake Junkil Been, Co-CEO of Neurophet, delivered a presentation titled "Neurophet in the Era of Paradigm Shift in Alzheimer's Disease: The Journey to IPO and Beyond," introducing the company's vision and roadmap. During the event, Neurophet introduced Neurophet AQUA AD, neuroimaging analysis software designed to monitor the prescription, treatment effects, and side effects of amyloid-targeted therapeutics for Alzheimer's disease. Neurophet AQUA AD quantitatively analyzes MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans, providing precise brain imaging analysis across the entire treatment process involving anti-amyloid antibody therapies. As the pharmaceutical and biotech industries accelerate the development of Alzheimer's disease treatments, the importance of adopting solutions that can precisely manage prescription, therapeutic efficacy, and potential side effects is increasingly coming into focus. Especially with Alzheimer's disease drugs such as Leqembi® (lecanemab) and Kisunla® (donanemab) requiring close monitoring of side effects, global demand and expectations are rising for Neurophet AQUA AD, a solution capable of analyzing brain imaging biomarkers related to adverse effects. At its exhibition booth, Neurophet is showcasing several key products, including Neurophet AQUA AD, Neurophet AQUA—a brain neurodegeneration imaging analysis software—and Neurophet SCALE PET, a quantitative analysis software for PET imaging. Through its participation in AAIC 2025, Neurophet is engaging in partnering efforts with global pharmaceutical companies and potential clients to pursue business development collaborations. The company is also holding meetings with leading Key Opinion Leaders (KOLs) in the field of neurology to highlight the unique strengths of its products and to build strategic collaborative networks. Jake Junkil Been, Co-CEO of Neurophet said that "Neurophet AQUA AD is gaining attention as a collaborative partner among various Korean and international companies in the field of brain imaging biomarkers," adding, "Through our participation in AAIC 2025, we plan to further accelerate global development collaborations for Neurophet AQUA AD and our other key products." AAIC 2025 is an international conference attended by dementia researchers and neurology clinicians, held in Toronto, Canada. This year's conference runs for five days, from July 27 to 31 (local time in Canada). About Neurophet Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS". Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
